PTIX Protagenic Therapeutics Inc.

Protagenic Therapeutics, Inc. is a biotechnology company, which specializes in the discovery and development of therapeutics to treat central nervous system disorders. It offers the PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.

$2.46
As of 07/23/2021     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  12/18/1996
Outstanding shares:  14,643,780
Average volume:  563,204
Market cap:   $36,170,137
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    
ISIN:        
Sedol:      

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   -66.49
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%